Serological profiles for HBV, HDV, HIV-1 and HTLV-1 in Saudi patients with a malignancy

Serologic markers for HBV, HDV, HIV-1 and HTLV-1 were tested in 42 patients with a primary hepatocellular carcinoma (PHC); 19 with a malignancy of epithelial origin (EPM) and 16 with a non-epithelial malignancy (NEPM) in the Gizan Area of Saudi Arabia. HBV exposure in 77 PHC, EPM and NEPM patients was 92.2 per cent for any marker (overall) while 75.3 per cent positive for HBsAg. 3.9 per cent positive for anti-HBc and 12.9 per cent positive for anti-HBs. There was no inter PHC, EPM, NEPM or intersex variation for an individual marker or total HBV exposure. Among HBsAg-positives, 9 of the 12 PHC tested, 7 of the 10 EPM, 1 of the 9 NEPM were anti-D IgG positive. The HDV prevalence was the lowest in NEPM (p < 0.01). In patients with a malignancy, all HBV and HDV markers were higher than those of control population, even though anti-HBs was lower (p < 0.001). The probable contribution through different viruses in pathogenesis of malignancies of different types should be ascertained through polymerase chain reaction for viral components, oncogenes, etc. on tumourous biopsy tissues. The aggravation in PHC morbidity in HBV hyperendemic foci through HIV infection should be monitored through tests for unintegrated and integrated viral DNA in tumorous and non-tumorous tissues.